Zelira Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Zelira Therapeutics does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-11.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-11.1%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if ZLD's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if ZLD's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

Zelira Therapeutics Piyasaya Karşı Temettü Getirisi

ZLD temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ZLD)	n/a
Pazarın Alt %25'i (AU)	2.6%
Pazarın En İyi %25'i (AU)	6.1%
Sektör Ortalaması (Pharmaceuticals)	2.2%
Analist tahmini (ZLD) (3 yıla kadar)	n/a

Önemli Temettü: Unable to evaluate ZLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate ZLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate ZLD's payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as ZLD has not reported any payouts.

Zelira Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024

Full year 2024 earnings released

Zelira Therapeutics Limited announced that it has received $1.4 million in funding

New major risk - Negative shareholders equity

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Full year 2023 earnings released: AU$0.55 loss per share (vs AU$1.49 loss in FY 2022)

Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released

New minor risk - Financial data availability

New major risk - Market cap size

Zelira Therapeutics Limited Announces Board Changes

Zelira Therapeutics Limited announced that it expects to receive $22 million in funding

First half 2023 earnings released: AU$0.38 loss per share (vs AU$0.81 loss in 1H 2022)

Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director

No independent directors

Zelira Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Zelira Therapeutics Launches ZYRAYDI™ B2b Technology to Create Pharma-Grade Cannabis Capsules & Tablets for Global Markets

Zelira Therapeutics Limited Completes Two-Thirds of Enrolment for Diabetic Nerve Pain Drug Trial

Full year 2022 earnings released: AU$1.54 loss per share (vs AU$1.29 loss in FY 2021)

Zelira's Zenivol™, the First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Zelira Therapeutics Ltd Publishes White Paper Detailing the Analysis of Longitudinal, Real-World Data Generated from Patients Using ZENIVOL

Zelira Therapeutics Ltd Announces Resignation of Harry Karelis as Non-Executive Vice Chairman

Zelira Therapeutics Limited Successfully Launches ITURA with CVSCM

No independent directors

Zelira Therapeutics Limited Appoints Timothy Slate as Director

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Zelira Therapeutics Limited Launches RAF FIVE Acne Treatment Products

Zelira Therapeutics Ltd Obtains IRB Approval for US Observational Clinical Pain Trial

Zelira Therapeutics Ltd. Announces Clinical Trial Results of Zelira's Zenivol Published in the Prestigiouspeer-Reviewed Journal Sleep

Zelira Therapeutics Limited Researchers Develops New Technology to Improves Delivery of CBD into Brain

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

MD & Director has left the company

Zelira Therapeutics Limited Announces Executive Changes

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Zelira Therapeutics Ltd Announces to Enter into A Binding Licensing Agreement with Alternative Solutions LLC

ZLD Partners with SprinJene to Launch CBD Toothpaste in US

Zelira Therapeutics Limited announced that it expects to receive AUD 1.999998 million in funding from Thorney Investment Group Australia Pty. Ltd.

Zelira Therapeutics Ltd. Announces Zenivol Launches in Australia After TGA Approves Release

Zelira Therapeutics Limited announced that it has received AUD 8.749378 million in funding

Zelira Therapeutics Limited announced that it expects to receive AUD 8.749378 million in funding

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin